Following the execution of a letter of execution in the attached form indicating the materials to be transferred, this organization agrees to be bound by the terms of the Uniform Biological Material Transfer Agreement (“RBMPU”) which was published in the Federal Register on 8 March 1995. AUTM agreed with NIH that, for convenience, AUTM would serve as a reference for UBMTA framework contracts signed by institutions that wish to use UBMTA for some or a full exchange of biological materials. AUTM archives the signed framework contracts in the form initially received and regularly publishes a list below. the name of the institution, the name and title of the official signatory and the date of signature of the framework contract. If, subsequently, an institution decides to withdraw its acceptance of the framework contract, AUTM will add the date on which the institution withdrew its authorisation. AUTM gives no guarantee as to the accuracy of the information transcribed in this list from the framework publication contracts or as to the actual authority of the signature. Each institution that relies on the AUTM rating does so at its own risk. While the NIH-SLA is recommended for the transmission of most materials, NIH policies have recognized that if materials have been patented, additional conditions may be required in an MTA to protect the rights of the institution providing the materials. The UBMTA takes into account that the transferred material can be protected by a patent and that it can be used for both patented and non-patented materials.
If both institutions are signatories to the UBMTA, it is sufficient to execute the implementation letter at each transfer. Non-signatories can sign the UBMTA framework contract and then use the implementation letter as a signatory to the UBMTA. Non-signatories can also use autm MTA templates, which are separate contracts based on the UBMTA. (ii) if the termination is carried out in accordance with point 13(b) or (d) above, the recipient will cease to use the material and, on the supplier`s instruction, return or destroy the remaining material. The Recipient, at its discretion, will proceed with the destruction of the Changes or will remain bound by the terms of this Agreement, as they apply to the Changes; and faculty members who come to or leave the UH must have an MTA before transferring materials from/to other institutions such as plasmids, cell lines, animals, etc. The use of UBMTA is not mandatory. When making the examiner`s decision, the boilerplate agreement of the University of Chicago Material Transfer Agreement (MTA) can be used. The material may only be used for teaching and academic research purposes; are not used in subjects, in clinical trials or for diagnostic purposes in human subjects, without the written consent of the supplier; only at the receiving organisation and only in the laboratory of the receiving scientist, under the direction of the receiving scientist or other persons working under his direct authority; and are not transferred to third parties within the BENEFICIARY ORGANIZATION without the prior written consent of the supplier. A Material Transfer Agreement (MTA) is a contract that governs the transfer of research material between two organizations when the recipient intends to use it for research purposes.
The MTA defines the rights of the supplier as well as the rights and obligations of the consignee with regard to the materials and any descendants, derivatives or modifications. Biological materials such as reactants, cell lines, plasmids, and vectors are the most frequently transferred materials, but ATMs can also be used for other types of materials such as chemical compounds, mouse models, and even some types of software. . . .